MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of ...

Detailed price information for Mbx Biosciences Inc (MBX-Q) from The Globe and Mail including charting and trades.

MBX Biosciences MBX, a clinical-stage biotech focused on developing treatments for endocrine and metabolic disorders, set terms for its initial public offering on Monday, with plans to offer 8.5 ...

CARMEL, Ind., June 16, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide ...

Microbix Biosystems Inc. ( MBX:CA) Q1 2026 Earnings Call February 12, 2026 10:00 AM EST All right. I think we can get started. Good morning, everyone. Thanks for joining us. We have an update from ...

It’s an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Therapeutics all going public with fine-tuned offerings. Of today’s three Nasdaq debuts, Bicara is set to make the ...

MBX Biosciences has added to the recent flurry of IPO filings. The biotech, which filed its paperwork weeks after raising $63.5 million privately, is seeking funding to take a would-be challenger to ...

MBX Biosciences (MBX) has drawn attention after posting a total return of about 261% over the past year, with recent gains in the month and past 3 months prompting closer scrutiny of its clinical ...

Positive results from MBX 1416 Phase 1 trial support Phase 2 advancement: In January 2025, the Company announced positive topline results from its Phase 1 single ascending dose and multiple ascending ...

Shares of newly IPO’ed peptide therapy developer MBX Biosciences (NASDAQ:MBX) traded sharply lower on Tuesday, even as several Wall Street firms launched its coverage with buy recommendations.

Phase 2 topline data from Avail trial expected in 3Q 2025. MBX completed enrollment of 64 participants, exceeding its original enrollment target, in the Phase 2 Avail trial of canvuparatide, a ...

Company is the third biotech to set price ranges for planned deals since Friday MBX Biosciences (MBX), a clinical-stage biotech focused on developing treatments for endocrine and metabolic disorders, ...